Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment

Agnes Juhasz, Aikaterini Vassilakos, Helen K. Chew, David Gandara, Yun Yen

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

This study describes the development of a rapid and practical real-time RT-PCR method to quantify ribonucleotide reductase M2 (RRM2) mRNA in tumor and peripheral white blood cells (WBCs) from patients treated with GTI-2040, an antisense drug currently in clinical trials. In order to assess target down-regulation by GTI-2040, RRM2 mRNA expression levels were analyzed in pre- and post-treatment samples from a phase II clinical trial of GTI-2040 combined with capecitabine in patients with metastatic breast cancer. Target gene RRM2 mRNA levels were evaluated using quantitative RT-PCR method: real-time PCR (TaqMan®) with fluorescein labeled probes on an ABI 7900HT instrument, with additional post-processing of the data to adjust for differences in total RNA in-put across the samples. Data are presented from a patient for whom both biopsy and PBMC samples were available, demonstrating applicability of this reproducible, highly sensitive real-time RT-PCR method for the detection and quantification of mRNAs for RRM2 in human WBC and tissue samples. By providing quantitative measurement of changes in target gene expression, this method may provide an opportunity to determine the correlation between target response to GTI-2040 antisense and clinical response in patients. Furthermore this assay may assess whether WBC samples are an appropriate surrogate tissue for approximating target down-regulation in the tumor.

Original languageEnglish
Pages (from-to)1299-1304
Number of pages6
JournalOncology Reports
Volume15
Issue number5
Publication statusPublished - May 1 2006
Externally publishedYes

Fingerprint

Real-Time Polymerase Chain Reaction
Messenger RNA
Leukocytes
Pharmaceutical Preparations
Down-Regulation
Phase II Clinical Trials
Therapeutics
Fluorescein
Neoplasms
Clinical Trials
RNA
Breast Neoplasms
Biopsy
Gene Expression
Polymerase Chain Reaction
GTI2040
ribonucleotide reductase M2
Genes
Capecitabine

Keywords

  • Clinical trials
  • Gene expression profiling
  • GTI-2040 antisense
  • Real-time PCR
  • RRM1
  • RRM2

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment. / Juhasz, Agnes; Vassilakos, Aikaterini; Chew, Helen K.; Gandara, David; Yen, Yun.

In: Oncology Reports, Vol. 15, No. 5, 01.05.2006, p. 1299-1304.

Research output: Contribution to journalArticle

Juhasz, Agnes ; Vassilakos, Aikaterini ; Chew, Helen K. ; Gandara, David ; Yen, Yun. / Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment. In: Oncology Reports. 2006 ; Vol. 15, No. 5. pp. 1299-1304.
@article{a7333b5eb1dd4fa1a4b756e542e3f753,
title = "Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment",
abstract = "This study describes the development of a rapid and practical real-time RT-PCR method to quantify ribonucleotide reductase M2 (RRM2) mRNA in tumor and peripheral white blood cells (WBCs) from patients treated with GTI-2040, an antisense drug currently in clinical trials. In order to assess target down-regulation by GTI-2040, RRM2 mRNA expression levels were analyzed in pre- and post-treatment samples from a phase II clinical trial of GTI-2040 combined with capecitabine in patients with metastatic breast cancer. Target gene RRM2 mRNA levels were evaluated using quantitative RT-PCR method: real-time PCR (TaqMan{\circledR}) with fluorescein labeled probes on an ABI 7900HT instrument, with additional post-processing of the data to adjust for differences in total RNA in-put across the samples. Data are presented from a patient for whom both biopsy and PBMC samples were available, demonstrating applicability of this reproducible, highly sensitive real-time RT-PCR method for the detection and quantification of mRNAs for RRM2 in human WBC and tissue samples. By providing quantitative measurement of changes in target gene expression, this method may provide an opportunity to determine the correlation between target response to GTI-2040 antisense and clinical response in patients. Furthermore this assay may assess whether WBC samples are an appropriate surrogate tissue for approximating target down-regulation in the tumor.",
keywords = "Clinical trials, Gene expression profiling, GTI-2040 antisense, Real-time PCR, RRM1, RRM2",
author = "Agnes Juhasz and Aikaterini Vassilakos and Chew, {Helen K.} and David Gandara and Yun Yen",
year = "2006",
month = "5",
day = "1",
language = "English",
volume = "15",
pages = "1299--1304",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment

AU - Juhasz, Agnes

AU - Vassilakos, Aikaterini

AU - Chew, Helen K.

AU - Gandara, David

AU - Yen, Yun

PY - 2006/5/1

Y1 - 2006/5/1

N2 - This study describes the development of a rapid and practical real-time RT-PCR method to quantify ribonucleotide reductase M2 (RRM2) mRNA in tumor and peripheral white blood cells (WBCs) from patients treated with GTI-2040, an antisense drug currently in clinical trials. In order to assess target down-regulation by GTI-2040, RRM2 mRNA expression levels were analyzed in pre- and post-treatment samples from a phase II clinical trial of GTI-2040 combined with capecitabine in patients with metastatic breast cancer. Target gene RRM2 mRNA levels were evaluated using quantitative RT-PCR method: real-time PCR (TaqMan®) with fluorescein labeled probes on an ABI 7900HT instrument, with additional post-processing of the data to adjust for differences in total RNA in-put across the samples. Data are presented from a patient for whom both biopsy and PBMC samples were available, demonstrating applicability of this reproducible, highly sensitive real-time RT-PCR method for the detection and quantification of mRNAs for RRM2 in human WBC and tissue samples. By providing quantitative measurement of changes in target gene expression, this method may provide an opportunity to determine the correlation between target response to GTI-2040 antisense and clinical response in patients. Furthermore this assay may assess whether WBC samples are an appropriate surrogate tissue for approximating target down-regulation in the tumor.

AB - This study describes the development of a rapid and practical real-time RT-PCR method to quantify ribonucleotide reductase M2 (RRM2) mRNA in tumor and peripheral white blood cells (WBCs) from patients treated with GTI-2040, an antisense drug currently in clinical trials. In order to assess target down-regulation by GTI-2040, RRM2 mRNA expression levels were analyzed in pre- and post-treatment samples from a phase II clinical trial of GTI-2040 combined with capecitabine in patients with metastatic breast cancer. Target gene RRM2 mRNA levels were evaluated using quantitative RT-PCR method: real-time PCR (TaqMan®) with fluorescein labeled probes on an ABI 7900HT instrument, with additional post-processing of the data to adjust for differences in total RNA in-put across the samples. Data are presented from a patient for whom both biopsy and PBMC samples were available, demonstrating applicability of this reproducible, highly sensitive real-time RT-PCR method for the detection and quantification of mRNAs for RRM2 in human WBC and tissue samples. By providing quantitative measurement of changes in target gene expression, this method may provide an opportunity to determine the correlation between target response to GTI-2040 antisense and clinical response in patients. Furthermore this assay may assess whether WBC samples are an appropriate surrogate tissue for approximating target down-regulation in the tumor.

KW - Clinical trials

KW - Gene expression profiling

KW - GTI-2040 antisense

KW - Real-time PCR

KW - RRM1

KW - RRM2

UR - http://www.scopus.com/inward/record.url?scp=33744991550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744991550&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 1299

EP - 1304

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -